MVP抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 50 μg, Lane 1-2: 231 cells, mouse kidney tissue, Primary antibody: P07423(MVP Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07423(MVP Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07423(MVP Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of MVP Antibodies**

MVP (Major Vault Protein), also known as LRP (lung resistance-related protein), is a conserved cytoplasmic protein predominantly associated with vault particles—large ribonucleoprotein complexes implicated in intracellular transport and drug resistance. Structurally, MVP forms the primary scaffold of vaults, which are linked to nuclear-cytoplasmic shuttling, though their exact physiological roles remain under investigation.

MVP gained attention due to its overexpression in multidrug-resistant cancers, particularly those resistant to chemotherapeutics like cisplatin and doxorubicin. Studies suggest MVP contributes to drug efflux or sequestration, enabling tumor cells to evade apoptosis. This association positioned MVP as a biomarker for poor prognosis and a potential therapeutic target.

MVP antibodies, developed to detect or inhibit MVP, have become vital tools in cancer research. Diagnostic applications include immunohistochemical staining to assess MVP levels in tumor biopsies, aiding in predicting treatment resistance. Therapeutically, MVP-targeting antibodies aim to sensitize resistant cancers by blocking MVP-mediated drug sequestration. Recent advances explore conjugating MVP antibodies with nanoparticles or chemotherapeutic agents for targeted delivery.

Research also investigates MVP's role in immune modulation and viral defense, broadening its relevance beyond oncology. Despite progress, challenges persist in understanding vault-specific MVP functions and optimizing antibody-based therapies. Current studies focus on elucidating MVP interactions and evaluating MVP antibody efficacy in preclinical models, highlighting its dual role as a biomarker and a candidate for novel anticancer strategies.